Sažetak Determination of metabolic profiles of new chemical entities is a key step in the
process of drug discovery, since it influences pharmacokinetic characteristics of therapeutic …

The discovery and development of a novel irreversible EGFR/HER2 dual tyrosine kinase
inhibitor SHR1258 (pyrotinib) for the treatment of HER2-postive breast cancer is presented …

Minimizing in vitro and in vivo testing in early drug discovery with the use of physiologically
based pharmacokinetic (PBPK) modeling and machine learning (ML) approaches has the …

Cultured cells are widely used in the evaluation of new drugs and drug delivery systems.
Cells can be grown at different levels of complexity ranging from simple reductionist models …

Allometric scaling on the basis of bodyweight raised to the power of 0.75 (AS0. 75) is
frequently used to scale size-related changes in plasma clearance (CL p) from adults to …

Early prediction of human clearance is often challenging, in particular for the growing
number of low-clearance compounds. Long-term in vitro models have been developed …

Interleukin 17A (IL-17A) is an interleukin cytokine whose dysregulation is implicated in
autoimmune disorders such as psoriasis, and monoclonal antibodies against the IL-17A …

Estimates of the human oral absolute bioavailability were made by using a physiological-
based pharmacokinetic model of absorption and the drug solubility at the gastrointestinal pH …

Sažetak Biologics mainly monoclonal antibodies (mAbs) and antibody-drug conjugates
(ADCs) as new therapeutics are becoming increasingly important biotherapeutics. This …

The purpose of this study was to perform a comparative analysis of various in vitro--in vivo
extrapolation (IVIVE) methods used for predicting hepatic metabolic clearance (CL) of drugs …